Tredje AP fonden decreased its holdings in shares of DaVita Inc. (NYSE:DVA – Free Report) by 50.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,424 shares of the company’s stock after selling 4,424 shares during the quarter. Tredje AP fonden’s holdings in DaVita were worth $662,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of DVA. SBI Securities Co. Ltd. purchased a new position in shares of DaVita during the fourth quarter worth about $41,000. Quarry LP purchased a new position in shares of DaVita during the third quarter worth about $60,000. Venturi Wealth Management LLC grew its holdings in shares of DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after purchasing an additional 152 shares in the last quarter. Versant Capital Management Inc boosted its stake in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after buying an additional 169 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock worth $76,000 after buying an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.
DaVita Price Performance
Shares of DaVita stock opened at $143.56 on Friday. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The company has a market cap of $11.48 billion, a PE ratio of 13.37, a P/E/G ratio of 1.07 and a beta of 0.99. The business has a 50 day moving average of $158.92 and a 200 day moving average of $157.62. DaVita Inc. has a 52 week low of $125.64 and a 52 week high of $179.60.
Wall Street Analyst Weigh In
Several analysts have issued reports on the company. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $166.33.
Check Out Our Latest Research Report on DVA
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Stories
- Five stocks we like better than DaVita
- How to Invest in the Best Canadian Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Buy Cheap Stocks Step by Step
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Plot Fibonacci Price Inflection Levels
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.